These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 29618348)

  • 21. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
    FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gypenoside LVI improves hepatic LDL uptake by decreasing PCSK9 and upregulating LDLR expression.
    Wang J; Wang YS; Huang YP; Jiang CH; Gao M; Zheng X; Yin ZQ; Zhang J
    Phytomedicine; 2021 Oct; 91():153688. PubMed ID: 34380071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
    Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
    Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake.
    Lupo MG; Macchi C; Marchianò S; Cristofani R; Greco MF; Dall'Acqua S; Chen H; Sirtori CR; Corsini A; Ruscica M; Ferri N
    Nutr Metab Cardiovasc Dis; 2019 Nov; 29(11):1245-1253. PubMed ID: 31439394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a.
    Cui CJ; Jin JL; Guo LN; Sun J; Wu NQ; Guo YL; Liu G; Dong Q; Li JJ
    J Transl Med; 2020 May; 18(1):195. PubMed ID: 32398139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
    Ye X; Qi J; Yu D; Wu Y; Zhu S; Li S; Wu Q; Ren G; Li D
    J Diabetes Complications; 2017 Apr; 31(4):726-734. PubMed ID: 28143735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol.
    Spolitu S; Okamoto H; Dai W; Zadroga JA; Wittchen ES; Gromada J; Ozcan L
    Circ Res; 2019 Jan; 124(1):38-51. PubMed ID: 30582457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulatory mechanism of mineral-balanced deep sea water on hypocholesterolemic effects in HepG2 hepatic cells.
    Lee KS; Kwon YS; Kim S; Moon DS; Kim HJ; Nam KS
    Biomed Pharmacother; 2017 Feb; 86():405-413. PubMed ID: 28012395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin.
    Susan-Resiga D; Girard E; Essalmani R; Roubtsova A; Marcinkiewicz J; Derbali RM; Evagelidis A; Byun JH; Lebeau PF; Austin RC; Seidah NG
    J Biol Chem; 2021 Oct; 297(4):101177. PubMed ID: 34508778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Piceatannol reduces resistance to statins in hypercholesterolemia by reducing PCSK9 expression through p300 acetyltransferase inhibition.
    Kim HJ; Lee J; Chung MY; Hong S; Park JH; Lee SH; Park SW; Choi HK; Hwang JT
    Pharmacol Res; 2020 Nov; 161():105205. PubMed ID: 32998069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α.
    Wang X; Chen X; Zhang X; Su C; Yang M; He W; Du Y; Si S; Wang L; Hong B
    EBioMedicine; 2020 Feb; 52():102650. PubMed ID: 32058941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
    Ruscica M; Ricci C; Macchi C; Magni P; Cristofani R; Liu J; Corsini A; Ferri N
    J Biol Chem; 2016 Feb; 291(7):3508-19. PubMed ID: 26668321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor.
    Abdelwahed KS; Siddique AB; Mohyeldin MM; Qusa MH; Goda AA; Singh SS; Ayoub NM; King JA; Jois SD; El Sayed KA
    Pharmacol Res; 2020 Aug; 158():104847. PubMed ID: 32438039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Soy β-Conglycinin Peptides on PCSK9 Protein Expression in HepG2 Cells.
    Macchi C; Greco MF; Ferri N; Magni P; Arnoldi A; Corsini A; Sirtori CR; Ruscica M; Lammi C
    Nutrients; 2021 Dec; 14(1):. PubMed ID: 35011066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of neolignans with PCSK9 downregulatory and LDLR upregulatory activities from Penthorum chinense and the potential in cholesterol uptake by transcriptional regulation of LDLR via SREBP2.
    Chae HS; Pel P; Cho J; Kim YM; An CY; Huh J; Choi YH; Kim J; Chin YW
    J Ethnopharmacol; 2021 Oct; 278():114265. PubMed ID: 34111537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).
    Ben Djoudi Ouadda A; Gauthier MS; Susan-Resiga D; Girard E; Essalmani R; Black M; Marcinkiewicz J; Forget D; Hamelin J; Evagelidis A; Ly K; Day R; Galarneau L; Corbin F; Coulombe B; Çaku A; Tagliabracci VS; Seidah NG
    Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):1996-2013. PubMed ID: 31553664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Cholesterol-Modulating Effect of Methanol Extract of Pigeon Pea (
    Chang HY; Wu JR; Gao WY; Lin HR; Chen PY; Chen CI; Wu MJ; Yen JH
    Molecules; 2019 Jan; 24(3):. PubMed ID: 30704067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.
    Gong Y; Ma Y; Ye Z; Fu Z; Yang P; Gao B; Guo W; Hu D; Ye J; Ma S; Zhang F; Zhou L; Xu X; Li Z; Yang T; Zhou H
    Metabolism; 2017 Nov; 76():32-41. PubMed ID: 28987238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aloe-emodin exerts cholesterol-lowering effects by inhibiting proprotein convertase subtilisin/kexin type 9 in hyperlipidemic rats.
    Su ZL; Hang PZ; Hu J; Zheng YY; Sun HQ; Guo J; Liu KY; Du ZM
    Acta Pharmacol Sin; 2020 Aug; 41(8):1085-1092. PubMed ID: 32203084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.